Department of Pathology and Laboratory Medicine, Women & Infants Hospital and the Alpert Medical School at Brown University, Providence, Rhode Island; Savjani Institute for Health Research, Windham, Maine.
Ansh Labs, Webster, Texas.
Fertil Steril. 2020 Apr;113(4):876-884.e2. doi: 10.1016/j.fertnstert.2019.12.012. Epub 2020 Mar 5.
To examine whether accounting for a woman's age and body mass index (BMI) would improve the ability of antimüllerian hormone (AMH) to distinguish between women with (cases) and without (controls) polycystic ovarian syndrome (PCOS).
An opportunistic case-control dataset of reproductive age women having evaluations for PCOS as defined by National Institutes of Health criteria.
Two medical centers in the United States enrolled women. Serum samples were analyzed for relevant analytes.
Women were between 18 and 39 years of age when samples and clinical information were collected. Residual samples had been stored for 2-17 years. AMH was measured via immunoassay.
None; this was an observational study.
Detection and false-positive rates for PCOS were computed for AMH results expressed as multiples of the median (MoM) both before and after adjustment for the woman's age and BMI.
Using unadjusted AMH MoM results, 168 cases (78%) cases were at or beyond the 90 centile of controls (2.47 MoM). After accounting for each woman's age and BMI, 188 (87%) of those women were beyond the 90 centile of controls (2.20 MoM), a significant increase (P = .015). The adjusted AMH MoM levels fitted logarithmic normal distributions well (mean, standard deviation for controls and cases of 0.0000, 0.2765 and 0.6884, 0.2874, respectively) and this allowed for computation of patient-specific PCOS risks.
Accounting for the woman's age and BMI resulted in significantly higher AMH-based detection rates for PCOS at a 10% false-positive rate, and patient-specific PCOS risks could be computed.
研究在抗苗勒管激素（AMH）中纳入女性年龄和体重指数（BMI）是否会提高其区分多囊卵巢综合征（PCOS）患者（病例）与非患者（对照）的能力。
这是一项基于机会的育龄期妇女病例对照研究，这些妇女因符合美国国立卫生研究院（NIH）标准而接受 PCOS 评估。
美国的两个医学中心招募了女性。对相关分析物进行血清样本分析。
采集样本和临床信息时，女性年龄在 18 至 39 岁之间。储存的剩余样本已保存 2-17 年。通过免疫测定法测量 AMH。
无；这是一项观察性研究。
使用 AMH 结果（倍数中位数（MoM））表示，分别在调整女性年龄和 BMI 之前和之后，计算 PCOS 的检出率和假阳性率。
使用未经调整的 AMH MoM 结果，168 例（78%）病例处于或超过对照的第 90 百分位数（2.47 MoM）。在考虑每个女性的年龄和 BMI 后，188 例（87%）女性超过了对照的第 90 百分位数（2.20 MoM），这是一个显著的增加（P=0.015）。调整后的 AMH MoM 水平很好地符合对数正态分布（对照组和病例的平均值、标准差分别为 0.0000、0.2765 和 0.6884、0.2874），这允许计算患者特异性 PCOS 风险。
在 10%的假阳性率下，纳入女性年龄和 BMI 会显著提高基于 AMH 的 PCOS 检出率，并可计算患者特异性 PCOS 风险。
